Clinical trial
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small…
NCT00324116 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00324116 |
|---|---|
| Title | Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions |
| Official title | A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions |
| Lead sponsor | Pfizer, Industry |
| Collaborators | ITEC GROUP 3 |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Macular Degeneration |
| Intervention type | Drug |
| Interventions | pegaptanib sodium (Macugen) |
| Enrollment | 81 |
| Start date | Jul 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | May 10, 2006 |
| Last update posted | Mar 23, 2010 |
| Countries | France |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: